MedTrace Logo

A Cardiac Liability Study of Varegacestat in Healthy Participants

NCT06855264 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2025-09-24

No results posted yet for this study

Summary

This clinical study is designed to study the effect of a single dose of varegacestat on cardiac repolarization in healthy adult participants.

Conditions

  • Healthy Volunteer

Interventions

DRUG

varegacestat

Single oral dose of varegacestat

DRUG

Placebo

Single oral dose of placebo

DRUG

Moxifloxacin 400 mg

Single oral dose of moxifloxacin

Sponsors & Collaborators

  • Immunome, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-02-24
Primary Completion
2025-04-08
Completion
2025-05-06
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06855264 on ClinicalTrials.gov